W146

Research use only, not for human use.

W146 is a selective and potent Sphingosine 1-phosphate receptor subtype 1 (S1PR1) antagonist that induces significant but transient hematolymphopenia in mice.

W146 is a selective antagonist of sphingosine-1-phosphate receptor 1 (S1PR1) with an EC50 value of 398 nM.

W146 is a S1PR1 antagonist with a Ki of ~70-80 nM. W146 pretreatment significantly increases activated cleaved caspase-3 levels. The reduced EPCs apoptosis which induced by S1P is completely abolished after treatment with W146.

W146 (5 mg/kg, ip, prior to AMD3100 administration) pre-treatment shows approximately 8-fold increase of KSL-HSPC mobilization, measured by the CFU-G/M colony forming assays, compared to that in mice treated with AMD3100 aloneThe W146-mediated augmentation of KSL-HSPC mobilization is specific, because pretreatment of mice with W140 is unable to produce any effect on AMD3100-stimulated KSL-HSPC mobilization. Injections of W146, W140, JTE013, or Cay10444 do not alter the basal WBC count in mice.Animal Model:Mice (4-6-week-old).Dosage:5 mg/kg.Administration:IP, 1 hour prior to AMD3100 (ADM) administration. Result: Significantly increased in KSL-HSPC mobilization compared to that in mice pretreated with dextran followed by AMD3100 administration.

——

Apoptosis

Apoptosis

Apoptosis | LPL Receptor

——

——

909725-61-7

342.37

C16H27N2O4P

>98% (HPLC)

In Vitro:?DMSO : 22.22 mg/mL (64.90 mM; Ultrasonic )

N(C([C@@H](CCP(=O)(O)O)N)=O)C1=CC(CCCCCC)=CC=C1

——

(-20℃)

With Ice Pack

≥ 2 years